Overview

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Status:
Recruiting

Trial end date:
2023-01-30

Target enrollment:

Participant gender:

Summary

This is a Phase 2, randomized, placebo-controlled crossover trial to assess the safety and efficacy of NB-001 in children and adolescents with 22q11DS that manifest commonly associated neuropsychiatric conditions.

Phase:

Phase 2

Details

Lead Sponsor:

Nobias Therapeutics, Inc.

Treatments:

5-((2-(6-Amino-9H-purin-9-yl) ethyl) amino)-1-pentanol